Aldeyra The • ALDX

Capital at risk.

About Aldeyra The
Ticker
info
ALDX
Trading on
info
NASDAQ
ISIN
info
US01438T1060
Industry
info
Biotechnology
Sector
info
Healthcare
CEO
info
Dr. Todd C. Brady M.D., Ph.D.
Headquarters
info
131 Hartwell Avenue, Lexington, MA, United States, 02421
Employees
info
9
Website
info
aldeyra.com
Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases. The company also develops ADX-629, an orally administered RASP modulator for treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment retinitis pigmentosa, as well as rare retinal diseases characterized by inflammation and vision loss. In addition, it develops ADX-246 in systemic immune-mediated disease; and ADX-248 in geographic atrophy. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.
Metrics
BasicAdvanced
Market cap
info
$367M
P/E ratio
info
-
EPS
info
-$0.94
Dividend Yield
info
0.00%
Beta
info
1.24
Forward P/E ratio
info
0
EBIDTA
info
$-59.9M
Ex dividend date
info
-
Price & volume
Market cap
info
$367M
Average daily volume
info
0.6M
90-day return
info
-
30-day return
info
-
7-day return
info
-
Dividends
Dividend per share
info
$0.00
Dividend yield
info
0.00%
Forward dividend per share
info
$0.00
Forward dividend yield
info
0.00%
Payout ratio
info
0.00%
Valuation
P/E ratio
info
0
Forward P/E
info
0
PEG ratio
info
0
Trailing P/E
info
0
Price to sales
info
0
Price to book
info
5.17
Earnings
EPS
info
-$0.94
EPS estimate (current quarter)
info
-$0.22
EPS estimate (next quarter)
info
-$0.22
EBITDA
info
$-59.9M
Revenues (TTM)
info
$0M
Revenues per share (TTM)
info
$0.00
Technicals
Beta
info
1.24
52-week High
info
$6.92
52-week Low
info
$2.71
50-day moving average
info
$5.49
200-day moving average
info
$4.90
Short ratio
info
11.15
Short %
info
7.43%
Management effectiveness
ROE (TTM)
info
58.55%
ROA (TTM)
info
29.71%
Profit margin
info
0.00%
Gross profit margin
info
$0M
Operating margin
info
0.00%
Growth
Quarterly earnings growth (YoY)
info
0.00%
Quarterly revenue growth (YoY)
info
0.00%
Share stats
Outstanding Shares
info
59.7M
Float
info
43.4M
Insiders %
info
3.65%
Institutions %
info
63.08%
Analyst Insights & forecasts
info

100% Buy

0% Hold

0% Sell

Based on information from 8 analysts.

Average price target

info
$10.00
Earnings per share (EPS) forecast
windowbar_chart_4_bars
Actual
info
Expected
info
Surprise
info
-$0.14
-$0.11
27.27%
Q1 • 24Beat
-$0.28
-$0.14
100.00%
Q2 • 24Beat
-$0.25
-$0.25
-
Q3 • 24Beat
-$0.27
-$0.22
24.25%
Q4 • 24Current
QuarterlyAnnual
Financial Performance
windowbar_chart_4_bars
Income StatementBalance SheetCash Flow
windowbar_chart_4_bars
Revenue
info
Net income
info
Profit margin
info
$0M
$-15.1M
∞%
Q3 • 24
$0M
$-15.8M
∞%
Q4 • 24
NaN%
4.60%
NaN%
QoQ growth
QuarterlyAnnual
Totals assets
info
Total liabilities
info
Debt to assets
info
$117M
$32.2M
27.47%
Q3 • 24
$105M
$33.6M
32.12%
Q4 • 24
10.84%
4.28%
16.95%
QoQ growth
QuarterlyAnnual
Operating
info
Investing
info
Financing
info
Free cash flow
info
$-8M
$5.3M
$-0.2M
$-8M
Q3 • 24
$-12M
$-1.6M
$0M
$-12M
Q4 • 24
50.93%
129.72%
103.94%
50.93%
QoQ growth
QuarterlyAnnual
Sentiment analysis

-1.5

Greed

+1.5

0.75

Last 30 days

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Past performance is no guarantee of future results. Your return may be affected by currency fluctuations and applicable fees and charges. The value of your investment may go up as well as down. When investing, your capital at risk.

Build your future fund today!

Automate your wealth-building journey and turn investing into a habit that your future self will be grateful for!

Capital at risk.

FAQs

How much is a Aldeyra The share?
Collapse

Aldeyra The shares are currently traded for undefined per share.

How many shares does Aldeyra The have?
Collapse

Aldeyra The currently has 59.7M shares.

Does Aldeyra The pay dividends?
Collapse

No, Aldeyra The doesn't pay dividends.

What is Aldeyra The 52 week high?
Collapse

Aldeyra The 52 week high is $6.92.

What is Aldeyra The 52 week low?
Collapse

Aldeyra The 52 week low is $2.71.

What is the 200-day moving average of Aldeyra The?
Collapse

Aldeyra The 200-day moving average is $4.90.

Who is Aldeyra The CEO?
Collapse

The CEO of Aldeyra The is Dr. Todd C. Brady M.D., Ph.D..

How many employees Aldeyra The has?
Collapse

Aldeyra The has 9 employees.

What is the market cap of Aldeyra The?
Collapse

The market cap of Aldeyra The is $367M.

What is the P/E of Aldeyra The?
Collapse

The current P/E of Aldeyra The is null.

What is the EPS of Aldeyra The?
Collapse

The EPS of Aldeyra The is -$0.94.

What is the PEG Ratio of Aldeyra The?
Collapse

The PEG Ratio of Aldeyra The is 0.

What do analysts say about Aldeyra The?
Collapse

According to the analysts Aldeyra The is considered a buy.